Tonmya (Sublingual Cyclobenzaprine HCl) in Fibromyalgia and Chronic Pain: A Psychopharmacologic Perspective – Brief Commentary
Psychopharmacology Bulletin · 2026-10-29 · 56 (4) · 153-156
DOI: 10.64719/pb.21627 ↗Abstract
Objective To review the psychopharmacologic profile of Tonmya (cyclobenzaprine HCl sublingual tablets), FDA-approved August 15, 2025, as the first new fibromyalgia therapy in over 15 years, and provide practical guidance for integration in cases with psychiatric comorbidity. Observations Tonmya targets sleep disruption, pain, and fatigue via receptor antagonism (5-HT2A serotonergic, α1-adrenergic, H1-histaminergic, M1-muscarinic), with sublingual delivery reducing daytime sedation. Phase 3 RESILIENT trial data showed significant pain reduction (p < 0.0001, effect size 0.38 at week 14), sleep/fatigue improvements, and favorable tolerability. Conclusions Psychiatrists and collaborators can use Tonmya adjunctively in fibromyalgia with mood/somatic features, emphasizing patient selection, documentation, monitoring, and multidisciplinary care to minimize risks and enhance outcomes in psychosomatic pain syndromes.
EUVIMED